Recro to Report Fourth Quarter and Year-End 2020 Financial Results Earlier Than Previously Announced
February 23, 2021 16:05 ET
|
Recro Pharma, Inc.
MALVERN, Pa., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Recro Announces Amendment to Athyrium Credit Facility
February 23, 2021 07:00 ET
|
Recro Pharma, Inc.
MALVERN, Pa., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Recro to Report Financial Results for Fourth Quarter And Year-End 2020 on February 26
February 19, 2021 16:05 ET
|
Recro Pharma, Inc.
MALVERN, Pa., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Recro Strengthens Leadership Team With Key Executive and Board Appointments
February 11, 2021 07:00 ET
|
Recro Pharma, Inc.
Company Names CDMO Industry Thought Leader, Jim Miller, to Board of Directors and Selects Ryan D. Lake as Dedicated Chief Financial OfficerRecent Appointments, including CEO David Enloe, Provide...
Recro Grants Inducement Award to New Chief Executive Officer
December 18, 2020 21:34 ET
|
Recro Pharma, Inc.
MALVERN, Pa., Dec. 18, 2020 (GLOBE NEWSWIRE) -- Recro (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for formulation, analytical...
Recro Announces Executive Changes
December 16, 2020 07:00 ET
|
Recro Pharma, Inc.
MALVERN, Pa., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Recro (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for formulation, analytical...
Recro Reports Third Quarter 2020 Financial Results
November 09, 2020 07:00 ET
|
Recro Pharma, Inc.
Company Secures Three-Year Renewal of License and Supply Agreement with Lannett, A Generics Pharmaceutical Company, for Manufacturing of Verelan PM®, Verelan SR® and Verapamil PM Strong Technical...
Recro to Report Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 9, 2020
November 02, 2020 07:00 ET
|
Recro Pharma, Inc.
MALVERN, Pa., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for formulation,...
Recro to Present at Oppenheimer Fall Healthcare Life Sciences & Medtech Summit
September 18, 2020 07:30 ET
|
Recro Pharma, Inc.
GAINESVILLE, Ga., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Recro (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for the development,...
Recro Reports Second Quarter 2020 Financial Results
August 10, 2020 07:00 ET
|
Recro Pharma, Inc.
Launches Clinical Trial Materials Business and Secures New Customers Company to Host Conference Call Today at 8:00 a.m. ET MALVERN, Pa., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Recro (Nasdaq:REPH), a...